Table 1.
Descriptive analysis of our cohort according to those with or without HCC. All patients were evaluated in out-patients' medical clinics every 3 months, with 12 visits every week
| HCC on 241 SVR patients | ||
| Parameter | Yes (n=6) | No (n=235) |
| Age (yrs), median (IQR) | 66 (60–69) | 65 (60.5–71) |
| Sex, n | ||
| Male | 6 | 198 |
| Female | 3 | 37 |
| BMI, median (IQR) | 24 (24–27) | 26 (24–28) |
| Smoke, n | 4 | 100 |
| Potus, n | 1 | 46 |
| Liver stiffness (kPa), | 34.6 (22–45) | 31.3 (18–39.1) |
| Treatment regimen* | ||
| SOF + RBV | 1 | 25 |
| SOF + LDV | 5 | 110 |
| SOF + SIM | 0 | 25 |
| SOF + DAK | 0 | 20 |
| 2D/3D | 0 | 55 |
| Treatment duration | ||
| 12 weeks | 5 | 213 |
| 24 weeks | 4 | 116 |
| Genotype, (n) | ||
| 1 | 4 | 134 |
| 2 | 1 | 82 |
| 3 | 1 | 20 |
| 4 | 0 | 1 |
| Child Pugh Score, n | ||
| A | 9 | 180 |
| B | 0 | 55 |
| HBsAg positivity | 0 | 6 |
| Portal vein thrombosis | 2/6 | 0 |
| OLTx | 0/6 | 0 |
| TACE | 3/6 | 0 |
| Exitus | 2/6 | 0 |
DAK, daklinza; 3D/2D, paritaprevir/ritonavir/ombitasvir (Viekirax) + Dasabuvir (Exviera); HBsAg, hepatitis B virus surface antigen; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; LDV, ledipasvir; OLTx, orthotopic liver transplant; RBV, ribavirin; SIM, simeprevir; SOF, sofosbuvir; SVR, sustained virological response; TACE, transarterial chemoembolization.